Q3 2024 Waldencast PLC Earnings Call Transcript
Key Points
- Waldencast PLC (WALD) reported a strong 34.6% increase in net revenue for Q3 2024, driven by robust growth in its Obagi Medical and Milk Makeup brands.
- Adjusted EBITDA rose by 134% to 16.3% of net revenue, showcasing significant profitability improvements.
- The company achieved a best-in-class adjusted gross margin of 74.8% for the first nine months of 2024, indicating strong operational efficiency.
- Milk Makeup expanded its global presence with new partnerships in Europe and launched successful new products, contributing to a 23.5% revenue growth.
- Obagi Medical saw a 45.5% growth in Q3, driven by successful product launches and improved inventory levels, reinforcing its position as a leading medical-grade skincare brand.
- Despite improvements, Waldencast PLC (WALD) still faces inventory challenges, particularly with Obagi Medical, which may impact growth into Q1 2025.
- The company is dealing with non-recurring costs related to an ongoing regulatory investigation, affecting its cash flow.
- Milk Makeup's adjusted gross profit margin declined due to a shift in product mix and timing of off-price sales.
- There is increased caution among retailers regarding inventory levels, which could affect future sales.
- The company anticipates less gross margin expansion in the future as it reaches its long-term targets, potentially limiting profitability growth.
Greetings, and welcome to the Waldencast third quarter and first nine months 2024 earnings call. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to Allison Malkin with ICR. Allison, please go ahead.
Thank you, and welcome to the Waldencast plc third quarter fiscal 2024 earnings call.
With me today are Michel Brousset, Founder and Chief Executive Officer; and Manuel Manfredi, Chief Financial Officer. For today's call, Michel will begin with an update on our business and vision and discuss the company's performance within the context of the beauty market.
Manuel will follow with a review of the third quarter and year-to-date performance and provide our fiscal 2024 outlook. Following this, Michel will share the strategic growth initiatives for our Milk Makeup and Obagi Medical brands. After the prepared remarks, the operator will open the call to take questions.
Before we start, I would like to remind you that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
